Kazia Therapeutics Ltd banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Australia AU
IPO date
Sep 1, 1994

Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.

Kazia Therapeutics Ltd Investor Relations

Address
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney, New South Wales
Australia

Management

Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (

CEO, MD & Exec. Director

Biography unavailable

Ms. Karen R. Krumeich

Chief Financial Officer

Biography unavailable

Dr. John E. Friend II, M.D.

Chief Medical Officer

Biography unavailable

Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD

Company Sec.

Biography unavailable

1 / 4